Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
Acupuncture helps cut fatigue, anxiety and depression in breast cancer patients using aromatase inhibitors

Acupuncture helps cut fatigue, anxiety and depression in breast cancer patients using aromatase inhibitors

Use of electroacupuncture (EA) - a form of acupuncture where a small electric current is passed between pairs of acupuncture needles - produces significant improvements in fatigue, anxiety and depression in as little as eight weeks for early stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors (AIs) to treat breast cancer. [More]
Researchers establish new strategy to help surgeons see entire tumor in patient

Researchers establish new strategy to help surgeons see entire tumor in patient

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence. [More]
EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). [More]
FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]
FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. [More]
Researchers find molecule that irreversibly interferes with activity of mutated cancer gene

Researchers find molecule that irreversibly interferes with activity of mutated cancer gene

UT Southwestern Medical Center cancer researchers have found a molecule that selectively and irreversibly interferes with the activity of a mutated cancer gene common in 30 percent of tumors. [More]
Cancer researchers find molecule that irreversibly interferes with KRAS gene

Cancer researchers find molecule that irreversibly interferes with KRAS gene

UT Southwestern Medical Center cancer researchers have found a molecule that selectively and irreversibly interferes with the activity of a mutated cancer gene common in 30 percent of tumors. [More]
Endoscopic resection not always best for localized, early-stage esophageal cancer: Study

Endoscopic resection not always best for localized, early-stage esophageal cancer: Study

A new study, published in the July, 2014, issue of the Journal of the National Cancer Institute by Northwestern Medicine- researchers, sheds new light on the risks associated with the growing popularity of endoscopic resection in the treatment of localized, early-stage esophageal cancer. [More]
FDA clears Lorus' LOR-253 IND application for treatment of hematologic malignancies

FDA clears Lorus' LOR-253 IND application for treatment of hematologic malignancies

Lorus Therapeutics Inc. today announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma. [More]
Adopting a comprehensive and integrative healing strategy for cancer

Adopting a comprehensive and integrative healing strategy for cancer

The cancer drugs, radiation therapy and cancer surgery available today help millions of people survive their cancer. [More]
PLM launches mobile apps to deliver medical information on cancer, heart disease conditions

PLM launches mobile apps to deliver medical information on cancer, heart disease conditions

IBM today announced that PLM, a Latin American healthcare sciences publisher, launched a library of mobile apps to deliver medical information on conditions such as cancer and heart disease. [More]
Smile Train, Biodigital  to showcase Virtual Surgery Simulator at TEDMED 2014

Smile Train, Biodigital to showcase Virtual Surgery Simulator at TEDMED 2014

Smile Train and its technology partner BioDigital have been selected to showcase their Virtual Surgery Simulator among leading global health innovations in The Hive at TEDMED 2014, which will take place in Washington, D.C. at The John F. Kennedy Center for the Performing Arts. [More]
CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil. [More]
Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Clinicians and researchers from Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University will present new findings from eight abstracts at the International Federation of Head and Neck Oncologic Societies World Congress being held July 26 - July 30 in New York. [More]
RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in the July, 2014 Rhode Island Medical Journal special edition, "RI Defeats Hep C" that eliminating hepatitis c virus infection (hep c or HCV) is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities. [More]
Molecular testing panel increases likelihood of performing correct surgery for thyroid cancer patients

Molecular testing panel increases likelihood of performing correct surgery for thyroid cancer patients

The routine use of a molecular testing panel developed at UPMC greatly increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer, report researchers from the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter. [More]
ESMO: Proposed EU General Data Protection Regulation may impact cancer research

ESMO: Proposed EU General Data Protection Regulation may impact cancer research

The European Society for Medical Oncology (ESMO), the leading pan-European association representing medical oncology professionals, has expressed concern that the proposed EU General Data Protection Regulation could make cancer research impossible and add a significant burden to both doctors and cancer patients. [More]
Experts at ABTA conference reveal possible causes, risk factors for brain tumors

Experts at ABTA conference reveal possible causes, risk factors for brain tumors

Today, nearly 700,000 people in the U.S. are living with a brain tumor, and yet, when it comes to pinpointing causes or risk factors, scientists are still searching for answers. [More]
CCC study provides hope that SapC-DOPS could be used for metastatic brain cancer treatment

CCC study provides hope that SapC-DOPS could be used for metastatic brain cancer treatment

Over half of patients being seen in the clinic for a diagnosed brain tumor have metastatic cancer, which has no treatment and detrimental outcomes in most cases. [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]